{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:27Z","timestamp":1788791367990,"version":"build-2803163510"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0008\/0003"],"award-info":[{"award-number":["RD16\/0008\/0003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008425","name":"Conseller\u00eda de Cultura, Educaci\u00f3n e Ordenaci\u00f3n Universitaria, Xunta de Galicia","doi-asserted-by":"crossref","award":["ED431G\/05"],"award-info":[{"award-number":["ED431G\/05"]}],"id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10792-019-01258-7","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T14:02:59Z","timestamp":1578578579000},"page":"1035-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Thyroid eye disease: current and potential medical management"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-716X","authenticated-orcid":false,"given":"Jessica M.","family":"Pouso-Diz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Abalo-Lojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"1258_CR1","volume-title":"Graves\u2019 disease and the manifestations of thyrotoxicosis","author":"L De Groot","year":"2000","unstructured":"De Groot L, Chrousos G, Dungan K et al (2000) Graves\u2019 disease and the manifestations of thyrotoxicosis. Endotext, South Dartmouth"},{"key":"1258_CR2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","volume":"165","author":"M Abraham-Nordling","year":"2011","unstructured":"Abraham-Nordling M, Bystr\u00f6m K, T\u00f6rring O, Lantz M, Berg G, Calissendorf J et al (2011) Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 165:899\u2013905","journal-title":"Eur J Endocrinol"},{"key":"1258_CR3","doi-asserted-by":"crossref","first-page":"249125","DOI":"10.1155\/2015\/249125","volume":"2015","author":"J Barrio-Barrio","year":"2015","unstructured":"Barrio-Barrio J, Sabater A, Bonet-Farriol E, Vel\u00e1zquez-Villoria \u00c1, Galofr\u00e9 J (2015) Graves\u2019 ophthalmopathy: VISA vs EUGOGO classification, assessment, and management. J Ophthalmol 2015:249125","journal-title":"J Ophthalmol"},{"key":"1258_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Bobodoris K, Eckstein A, Kahaly G, Marcocci C et al (2016) The 2016 European thyroid association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid 5:9\u201326","journal-title":"Eur Thyroid"},{"key":"1258_CR5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/IIO.0b013e318293c44e","volume":"53","author":"C Brice\u00f1o","year":"2013","unstructured":"Brice\u00f1o C, Gupta S, Douglas R (2013) Advances in the management of thyroid eye disease. Int Ophthalmol 53:93\u2013101","journal-title":"Int Ophthalmol"},{"key":"1258_CR6","first-page":"422","volume":"6","author":"E Rivera-Grana","year":"2015","unstructured":"Rivera-Grana E, Lin P, Suhler E, Rosenbaum J (2015) Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol 6:422","journal-title":"J Clin Exp Ophthalmol"},{"key":"1258_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Graves\u2019 orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2:259\u2013269","journal-title":"Eur Thyroid J."},{"key":"1258_CR8","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","volume":"97","author":"P Laurberg","year":"2012","unstructured":"Laurberg P, Berman D, B\u00fclow Pedersen I, Andersen S, Carl\u00e9 A (2012) Incidence and clinical presentation of moderate to severe graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325\u20132332","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag D, Lane C, Lazarus J, Baldeschi L, Boboridis K, Dickinson A et al (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves\u2019 Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91:455\u2013458","journal-title":"Br J Ophthalmol"},{"key":"1258_CR10","first-page":"134","volume":"5","author":"W Wiersinga","year":"2007","unstructured":"Wiersinga W (2007) Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. Diabetes Endocrinol 5:134\u2013142","journal-title":"Diabetes Endocrinol"},{"key":"1258_CR11","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/jc.2005-2537","volume":"91","author":"H Inaba","year":"2006","unstructured":"Inaba H, Martin W, De Groot A, Qin S, De Groot L (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves\u2019 disease. J Clin Endocrinol Metab 91:2286\u20132294","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1507\/endocrj.44.633","volume":"44","author":"T Akamizu","year":"1997","unstructured":"Akamizu T, Mori T, Nakao K (1997) Pathogenesis of Graves\u2019 disease: molecular analysis of anti-thyrotropin receptor antibodies. Endocr J 44:633\u2013646","journal-title":"Endocr J"},{"key":"1258_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fendo.2016.00120","volume":"7","author":"H Inaba","year":"2016","unstructured":"Inaba H, De Groot L, Akamizu T (2016) Thyrotropin receptor epitope and human leukocyte antigen in Graves\u2019 disease. Front Endocrinol (Lausanne) 7:120","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1258_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","volume":"26","author":"S Iyer","year":"2012","unstructured":"Iyer S, Bahn R (2012) Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor. Pract Res Clin Endocrinol Metab 26:281\u2013289","journal-title":"Pract Res Clin Endocrinol Metab"},{"key":"1258_CR15","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang C, Afifiyan N, Sinha Hikim A et al (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol 181:4387\u20134405","journal-title":"J Immunol"},{"key":"1258_CR16","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","volume":"178","author":"R Douglas","year":"2007","unstructured":"Douglas R, Gianoukakis A, Kamat S, Smith T (2007) Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J Immunol 178:3281\u20133287","journal-title":"J Immunol"},{"key":"1258_CR17","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"R Douglas","year":"2008","unstructured":"Douglas R, Naik V, Hwang C, Afifiyan N, Gianoukakis A, Sand D et al (2008) B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 181:5768\u20135774","journal-title":"J Immunol"},{"key":"1258_CR18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"T Smith","year":"2017","unstructured":"Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R et al (2017) Teprotumumab for thyroid-associated ophthalmopy. N Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"key":"1258_CR19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"J Khong","year":"2016","unstructured":"Khong J, McNab A, Ebeling P, Craig J, Selva D (2016) Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 100:142\u2013150","journal-title":"Br J Ophthalmol"},{"key":"1258_CR20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning J (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475","journal-title":"Nat Rev Immunol"},{"key":"1258_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2010.02470.x","volume":"73","author":"G Lied","year":"2011","unstructured":"Lied G, Berstad A (2011) Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 73:1\u20137","journal-title":"Scand J Immunol"},{"key":"1258_CR22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3899\/jrheum.130677","volume":"40","author":"M Leandro","year":"2013","unstructured":"Leandro M, Cambridge G (2013) Expression of B cell activating factor (BAFF) and BAFF-biding receptors in rheumatoid arthritis. J Rheumathol 40:1247\u20131250","journal-title":"J Rheumathol"},{"key":"1258_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaut.2018.05.002","volume":"92","author":"E Theodorou","year":"2018","unstructured":"Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M et al (2018) B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun 92:87\u201392","journal-title":"J Autoimmun"},{"key":"1258_CR24","first-page":"2876","volume":"8","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Li J, Wei B, Xu Z (2015) BAFF level increased in patients with autoimmune hemolytic anemia. Int J Clin Exp Med 8:2876\u20133882","journal-title":"Int J Clin Exp Med"},{"key":"1258_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/01676831003668443","volume":"29","author":"L van Steensel","year":"2010","unstructured":"van Steensel L, Dik W (2010) The orbital fibroblast: a key player and target for therapy in Graves\u2019 ophthalmopathy. Orbit 29:202\u2013206","journal-title":"Orbit"},{"key":"1258_CR26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1210\/jc.2012-1020","volume":"97","author":"L van Steensel","year":"2012","unstructured":"van Steensel L, Hooijkaas H, Paridaens D, van de Bosch W, Kuijpers R, Drexhage H et al (2012) PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves\u2019 ophthalmopathy patients. J Clin Endocrinol Metab 97:944\u2013953","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000367968","volume":"3","author":"S Virakul","year":"2014","unstructured":"Virakul S, van Steensel L, Dalm V, Paridaens D, van Hagen P, Dik W (2014) Platelet-derived growth factor: a key factor in the pathogenesis of Graves\u2019 ophthalmopathy and potential target for treatment. Eur Thyroid 3:217\u2013226","journal-title":"Eur Thyroid"},{"key":"1258_CR28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","volume":"142","author":"W Dik","year":"2016","unstructured":"Dik W, Virakul S, van Steensel L (2016) Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves\u2019 ophthalmopathy. Exp Eye Res 142:83\u201391","journal-title":"Exp Eye Res"},{"key":"1258_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"R Bahn","year":"2010","unstructured":"Bahn R (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738","journal-title":"N Engl J Med"},{"key":"1258_CR30","first-page":"414","volume":"33","author":"T Smith","year":"2010","unstructured":"Smith T (2010) Pathogenesis of Graves\u2019 orbitopathy: a 2010 update. J Endocrinol 33:414\u2013421","journal-title":"J Endocrinol"},{"key":"1258_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"M Mourist","year":"1997","unstructured":"Mourist M, Prummel M, Wiersinga W, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47:9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-15-1164","volume":"175","author":"I Campi","year":"2016","unstructured":"Campi I, Vannucchi G, Salvi M (2016) Therapy of endocrine disease: endocrine dilemma: management of Graves\u2019 orbitopathy. Eur J Endocrinol 175:117\u2013133","journal-title":"Eur J Endocrinol"},{"key":"1258_CR33","unstructured":"Salvi M (2012) EUGOGO Atlas: EUGOGO protocol for assessment of Graves\u2019 orbitopathy and completion of case record form Milan: EUGOGO"},{"key":"1258_CR34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9394(69)91246-X","volume":"68","author":"S Werner","year":"1969","unstructured":"Werner S (1969) Classification of the eye changes of Graves\u2019 disease. Am J Ophthalmol 68:646\u2013648","journal-title":"Am J Ophthalmol"},{"key":"1258_CR35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","volume":"83","author":"S Werner","year":"1977","unstructured":"Werner S (1977) Modification of the classification of the eye changes of Graves\u2019 disease. Am J Ophthalmol 83:725\u2013727","journal-title":"Am J Ophthalmol"},{"key":"1258_CR36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","volume":"169","author":"M Prummel","year":"1993","unstructured":"Prummel M, Wiersinga W (1993) Smoking and risk of Graves\u2019 disease. JAMA 169:479\u2013482","journal-title":"JAMA"},{"key":"1258_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","volume":"79","author":"W Wiersinga","year":"2013","unstructured":"Wiersinga W (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145\u2013151","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Tanda M, Manetti L, Dell\u2019Unto E, Bartolomei M et al (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632\u2013635","journal-title":"Ann Intern Med"},{"key":"1258_CR39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477\u2013481","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A, Quadbeck B, Mueller G, Rettenmeier A, Hoermann R, Mann K et al (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87:773\u2013776","journal-title":"Br J Ophthalmol"},{"key":"1258_CR41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","volume":"26","author":"L Bartalena","year":"2012","unstructured":"Bartalena L (2012) Prevention of Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:371\u2013379","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1258_CR42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/eje.1.01991","volume":"153","author":"G Krassas","year":"2005","unstructured":"Krassas G, Segni M, Wiersinga W (2005) Childhood Graves\u2019 ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153:515\u2013521","journal-title":"Eur J Endocrinol"},{"key":"1258_CR43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","volume":"93","author":"A Eckstein","year":"2009","unstructured":"Eckstein A, L\u00f6sch C, Glowacka D, Schott M, Mann K, Esser J et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves\u2019 ophthalmopathy. Br J Ophthalmol 93:1052\u20131056","journal-title":"Br J Ophthalmol"},{"key":"1258_CR44","first-page":"426898","volume":"22","author":"K Termote","year":"2014","unstructured":"Termote K, Decallonne B, Mombaerts I (2014) The influence of prior hyperthyroidism on euthyroid Graves\u2019 ophthalmopathy. J Ophthalmol 22:426898","journal-title":"J Ophthalmol"},{"key":"1258_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros P, Heged\u00fcs L, Bartalena L, Marcocci C, Kahaly G, Baldeschi L et al (2017) Graves\u2019 orbitopathy are a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72","journal-title":"Orphanet J Rare Dis"},{"key":"1258_CR46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","volume":"121","author":"G Bartley","year":"1996","unstructured":"Bartley G, Fatourechi V, Kadrmas E, Jacobsen S, Ilstrup D, Garrity J et al (1996) Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284\u2013290","journal-title":"Am J Ophthalmol"},{"key":"1258_CR47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena L, Marccocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A (1989) Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349\u20131352","journal-title":"N Engl J Med"},{"key":"1258_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda M, Dell\u2019Unto E et al (1998) Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy. N Engl J Med 338:73\u201378","journal-title":"N Engl J Med"},{"key":"1258_CR49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2009-2130","volume":"95","author":"A Lai","year":"2010","unstructured":"Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E et al (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves\u2019 orbitopathy: a retrospective cohort study. J Clin Endocrinol Med 95:1333\u20131337","journal-title":"J Clin Endocrinol Med"},{"key":"1258_CR50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000444482","volume":"5","author":"R Negro","year":"2016","unstructured":"Negro R, Attanasio R, Grimaldi F, Guglielmi R, Papini E, AME (Associazione Medici Endocrinology) et al (2016) A 2015 Italian survey of clinical practice patterns in the management of Graves\u2019 disease: comparison with European and North American surveys. Eur Thyroid J 5:112\u2013119","journal-title":"Eur Thyroid J"},{"key":"1258_CR51","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2009-0506","volume":"94","author":"G Vannucchi","year":"2009","unstructured":"Vannucchi G, Campi I, Covelli D, Dazzi D, Curr\u00f2 N, Simonetta S et al (2009) Graves\u2019 orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381\u20133386","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR52","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"Tr\u00e4isk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J et al (2009) Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700\u20133707","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","volume":"130","author":"L Tallstedt","year":"1994","unstructured":"Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves\u2019 ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494\u2013497","journal-title":"Eur J Endocrinol"},{"key":"1258_CR54","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","volume":"90","author":"P Perros","year":"2005","unstructured":"Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 90:5321\u20135323","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR55","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1210\/jc.2014-4542","volume":"100","author":"N Watanabe","year":"2015","unstructured":"Watanabe N, Noh J, Kozaki A, Iwaku K, Sekiya K, Kosuga Y et al (2015) Radioiodine-associated exacerbation of Graves\u2019 orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100:2700\u20132708","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","volume":"52","author":"M Gerding","year":"2000","unstructured":"Gerding M, van der Meer J, Broenink M, Bakker O, Wiersinga W, Prummel M (2000) Association of thyrotropin receptor antibodies with the clinical features of Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 52:267\u2013271","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR57","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"A Eckstein","year":"2006","unstructured":"Eckstein A, Plicht M, Lax H, Neuh\u00e4user M, Mann K, Lederbogen S et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of disease. J Clin Endocrinol Metab 91:3464\u20136470","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR58","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly G, Krassas G, Bartalena L, Prummel M, Stahl M et al (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"1258_CR59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002341-200405000-00001","volume":"20","author":"K Morgenstern","year":"2004","unstructured":"Morgenstern K, Evanchan J, Foster J, Cahill K, Burns J, Holck D et al (2004) Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic Plast Reconstr Surg 20:181\u2013185","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1258_CR60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/eye.2008.165","volume":"23","author":"P Costa","year":"2009","unstructured":"Costa P, Saraiva F, Pereira I, Monteiro M, Matayoshi S (2009) Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye (London) 23:767\u2013773","journal-title":"Eye (London)"},{"key":"1258_CR61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jfo.2016.10.016","volume":"40","author":"A Nava Casta\u00f1eda","year":"2017","unstructured":"Nava Casta\u00f1eda A, Tovilla Canales J, Garnica Hayashi L, Velasco Y Levy A (2017) Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A. J Fr Ophtthalmol 40:279\u2013284","journal-title":"J Fr Ophtthalmol"},{"key":"1258_CR62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.beem.2011.11.005","volume":"26","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, Marin\u00f2 M (2012) Treatment of mild, moderate-to-severe and very severe Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab 26:325\u2013337","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1258_CR63","first-page":"186","volume":"34","author":"M Bhatti","year":"2014","unstructured":"Bhatti M, Dutton J (2014) Thyroid eye disease: therapy in the active phase. Best Pract Res Clin Endocrinol Metab 34:186\u2013197","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1258_CR64","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s10792-017-0694-0","volume":"38","author":"R Kumari","year":"2018","unstructured":"Kumari R, Chandra Saha B (2018) Advances in the management of thyroid eye disease: an overview. Int Ophthalmol 38:2247\u20132255","journal-title":"Int Ophthalmol"},{"key":"1258_CR65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-014-0477-6","volume":"48","author":"L Duntas","year":"2015","unstructured":"Duntas L, Benvenga S (2015) Selenium: an element for life. Endocrine 48:756\u2013775","journal-title":"Endocrine"},{"key":"1258_CR66","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1210\/jc.2015-2222","volume":"100","author":"Q Wu","year":"2015","unstructured":"Wu Q, Rayman M, Lv H, Schomburg L, Cui B, Gao C et al (2015) Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 100:4037\u20134047","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR67","doi-asserted-by":"crossref","first-page":"17964","DOI":"10.1074\/jbc.M703075200","volume":"282","author":"H Vunta","year":"2007","unstructured":"Vunta H, Davis F, Palempalli U, Bhat D, Arner R, Thompson J et al (2007) The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta 12,14-prostaglandin J2 in macrophages. J Biol Chem 282:17964\u201317973","journal-title":"J Biol Chem"},{"key":"1258_CR68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000324442","volume":"75","author":"L Saranac","year":"2011","unstructured":"Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B (2011) Why is the thyroid so prone to autoimmune disease? Horm Res Paediatr 75:157\u2013165","journal-title":"Horm Res Paediatr"},{"key":"1258_CR69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrendo.2011.174","volume":"8","author":"L Schomburg","year":"2011","unstructured":"Schomburg L (2011) Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 8:160\u2013171","journal-title":"Nat Rev Endocrinol"},{"key":"1258_CR70","doi-asserted-by":"crossref","first-page":"1297658","DOI":"10.1155\/2017\/1297658","volume":"2017","author":"M Ventura","year":"2017","unstructured":"Ventura M, Melo M, Carrilho F (2017) Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol 2017:1297658","journal-title":"Int J Endocrinol"},{"key":"1258_CR71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1017\/S002966511000176X","volume":"69","author":"B Carlson","year":"2010","unstructured":"Carlson B, Yoo M, Shrimali R, Irons R, Gladyshev V, Hatfield D et al (2010) Role of selenium-containing proteins in T-cell and macrophage function. Proc Nutr Soc 69:300\u2013310","journal-title":"Proc Nutr Soc"},{"key":"1258_CR72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cccn.2003.10.028","volume":"341","author":"V Vrca","year":"2004","unstructured":"Vrca V, Skerb F, Cepelak I, Romic Z, Mayer L (2004) Supplementation with antioxidants in the treatment of Graves\u2019 disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 341:55\u201363","journal-title":"Clin Chim Acta"},{"key":"1258_CR73","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1210\/jc.2017-01736","volume":"102","author":"G Kahaly","year":"2017","unstructured":"Kahaly G, Riedl M, K\u00f6nig J, Diana T, Schomburg L (2017) Double-blind, placebo-controlled, randomized trial of selenium in Graves\u2019hiperthyroidism. J Clin Endocrinol Metab 102:4333\u20134341","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ICU.0000000000000402","volume":"28","author":"D Strianese","year":"2017","unstructured":"Strianese D (2017) Update of Graves\u2019 disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol 28:505\u2013513","journal-title":"Curr Opin Ophthalmol"},{"key":"1258_CR75","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.numecd.2010.10.001","volume":"20","author":"S Stranges","year":"2010","unstructured":"Stranges S, Navas-Acien A, Rayman M, Guallar E (2010) Selenium status and cardiometabolic health: state of evidence. Nutr Cardiovasc Dis 20:754\u2013760","journal-title":"Nutr Cardiovasc Dis"},{"key":"1258_CR76","doi-asserted-by":"crossref","first-page":"12561268","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"M Rayman","year":"2012","unstructured":"Rayman M (2012) Selenium and human health. Lancet 379:12561268","journal-title":"Lancet"},{"key":"1258_CR77","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/nu5041349","volume":"5","author":"C Rocourt","year":"2013","unstructured":"Rocourt C, Cheng W (2013) Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients 5:1349\u20131365","journal-title":"Nutrients"},{"key":"1258_CR78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/acta.0.1280041","volume":"128","author":"A Heufelder","year":"1993","unstructured":"Heufelder A, Wenzel B, Bahn R (1993) Glucocorticoids modulate the synthesis and expression of a 72\u00a0kDa heat shock protein in cultured Graves\u2019 retroocular fibroblast. Acta Endocrinol (Copenh) 128:41\u201350","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1258_CR79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/eje.0.1440311","volume":"144","author":"G Krassas","year":"2001","unstructured":"Krassas G, Heufelder A (2001) Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144:311\u2013318","journal-title":"Eur J Endocrinol"},{"key":"1258_CR80","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto K, Kahaly G (2011) Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320\u2013332","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","volume":"30","author":"R Ayabe","year":"2014","unstructured":"Ayabe R, Rootman D, Hwang C, Ben-Artzi A, Golberg R (2014) Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthal Plast Reconstr Surg 30:415\u2013419","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1258_CR82","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","volume":"94","author":"H Stiebel-Kalish","year":"2009","unstructured":"Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L (2009) Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 94:2708\u20132716","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR83","doi-asserted-by":"crossref","first-page":"e0139544","DOI":"10.1371\/journal.pone.0139544","volume":"10","author":"P Mou","year":"2015","unstructured":"Mou P, Jiang L, Zhang Y, Li Y, Lou H, Zeng C et al (2015) Common immunosuppressive monotherapy for Graves\u2019 ophthalmopathy: a meta-analysis. PLoS ONE 10:e0139544","journal-title":"PLoS ONE"},{"key":"1258_CR84","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"G Kahaly","year":"2005","unstructured":"Kahaly G, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90:5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR85","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C (2000) Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 21:168\u2013199","journal-title":"Endocr Rev"},{"key":"1258_CR86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-14-0712","volume":"172","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R et al (2015) Intravenous glucocorticoid therapy for Graves\u2019 ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172:269\u2013276","journal-title":"Eur J Endocrinol"},{"key":"1258_CR87","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas G, Wiersinga W, Marcocci C, Salvi M et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopahty. J Clin Endocrinol Metab 97:4454\u20134463","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR88","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1210\/jc.2014-4463","volume":"100","author":"D Covelli","year":"2015","unstructured":"Covelli D, Vannucchi G, Campi I, Curr\u00f2 N, D\u2019Ambrosio R, Maggioni M et al (2015) Statins may increase the risk of liver dysfunction in patients treated with steroids for active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100:1731\u20131737","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR89","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","volume":"38","author":"E Sisti","year":"2015","unstructured":"Sisti E, Menconi F, Leo M, Profilo M, Mautone T, Mazzi B et al (2015) Long-term outcome of Graves\u2019 orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661\u2013668","journal-title":"J Endocrinol Invest"},{"key":"1258_CR90","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","volume":"24","author":"P Macchia","year":"2001","unstructured":"Macchia P, Bagattini M, Lupoli G, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy. J Endocrinol Invest 24:152\u2013158","journal-title":"J Endocrinol Invest"},{"key":"1258_CR91","first-page":"1200","volume":"85","author":"J Smith","year":"2001","unstructured":"Smith J, Rosenbaum J (2001) A role methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 85:1200\u20131224","journal-title":"Br J Ophthalmol"},{"key":"1258_CR92","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3233\/JAD-160222","volume":"56","author":"M Emon","year":"2017","unstructured":"Emon M, Kodamullil A, Karki R, Younesi E, Hofmann-Apitius M (2017) Using drugs as molecular probes: a computational chemical biology approach in neurodegenerative disease. J Alzheimers Dis 56:677\u2013686","journal-title":"J Alzheimers Dis"},{"key":"1258_CR93","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"M Prummel","year":"1989","unstructured":"Prummel M, Mourits M, Berghout A, Krenning E, van der Gaag R, Koornneef L et al (1989) Prednisone and cyclosporine in treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med 321:1353\u20131359","journal-title":"N Engl J Med"},{"key":"1258_CR94","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W et al (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16:415\u2013422","journal-title":"Eur J Clin Invest"},{"key":"1258_CR95","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pr.109.002006","volume":"63","author":"P Engel","year":"2011","unstructured":"Engel P, G\u00f3mez-Puerta J, Ramos-Casals M, Lozano F, Bosch X (2011) Therapeutic targeting of B cells for rheumatic autoimmune disease. Pharmacol Rev 63:127\u2013156","journal-title":"Pharmacol Rev"},{"key":"1258_CR96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","volume":"130","author":"M Salvi","year":"2012","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Introna M, Rossi S, Bonara P et al (2012) Small dose of Rituximab for Graves\u2019 orbitopathy: new insights into the mechanism of action. Arch Ophthalmol 130:122\u2013124","journal-title":"Arch Ophthalmol"},{"key":"1258_CR97","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98:4291\u20134299","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR98","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covell D, Dazzi D et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:422\u2013431","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"M Stan","year":"2015","unstructured":"Stan M, Garrity J, Carraza Leon B, Prabin T, Bradley E, Bahn R (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100:432\u2013441","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"M Stan","year":"2017","unstructured":"Stan M, Salvi M (2017) Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy\u2014lessons from randomized control trials. Eur J Endocrinol 176:101\u2013109","journal-title":"Eur J Endocrinol"},{"key":"1258_CR101","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"R van Vollenhoven","year":"2013","unstructured":"van Vollenhoven R, Emery P, Bingham CO, Keystone E, Fleischmann R, Furst D et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496\u20131502","journal-title":"Ann Rheum Dis"},{"key":"1258_CR102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","volume":"1","author":"J Descotes","year":"2009","unstructured":"Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104\u2013111","journal-title":"MAbs"},{"key":"1258_CR103","doi-asserted-by":"crossref","first-page":"e0130322","DOI":"10.1371\/journal.pone.0130322","volume":"10","author":"H Chen","year":"2015","unstructured":"Chen H, Shan S, Mester T, Wei Y, Douglas R (2015) TSH-Mediated TNF\u03b1 production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS ONE 10:e0130322","journal-title":"PLoS ONE"},{"key":"1258_CR104","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","volume":"148","author":"K Donahue","year":"2008","unstructured":"Donahue K, Gartlehner G, Jonas D, Lux L, Thieda P, Jonas B et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124\u2013134","journal-title":"Ann Intern Med"},{"key":"1258_CR105","first-page":"457","volume":"109","author":"J Komorowski","year":"2007","unstructured":"Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, K\u0142ysik A, Go\u015b R et al (2007) Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna 109:457\u2013460","journal-title":"Klin Oczna"},{"key":"1258_CR106","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch W, van der Loos T, Krenning E, van Hagen P (2005) The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye (Lond) 19:1286\u20131289","journal-title":"Eye (Lond)"},{"key":"1258_CR107","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.oftal.2018.04.011","volume":"93","author":"L de-Pablo-G\u00f3mez-de-Lia\u00f1o","year":"2018","unstructured":"de-Pablo-G\u00f3mez-de-Lia\u00f1o L, Fern\u00e1ndez-Vigo J, Troyano-Rivas J, Ni\u00f1o-Rueda C, Romo-L\u00f3pez \u00c1, G\u00f3mez de Lia\u00f1o R (2018) Response to tocilizumab treatment in Graves\u2019 ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography. Arch Soc Esp Oftalmol 93:386\u2013391","journal-title":"Arch Soc Esp Oftalmol"},{"key":"1258_CR108","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"J P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras J, Alvarez-L\u00f3pez A, G\u00f3mez E (2014) Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Plast Reconstr Surg 30:162\u2013167","journal-title":"Plast Reconstr Surg"},{"key":"1258_CR109","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"J P\u00e9rez-Moreiras","year":"2018","unstructured":"P\u00e9rez-Moreiras J, Gomez-Reino J, Maneiro J, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez F et al (2018) Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181\u2013190","journal-title":"Am J Ophthalmol"},{"key":"1258_CR110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","volume":"41","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15\u201323","journal-title":"J Rheumatol"},{"key":"1258_CR111","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2014-1580","volume":"99","author":"H Chen","year":"2014","unstructured":"Chen H, Mester T, Raychaudhuri N, Kauh C, Gupta S, Smith T et al (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99:1635\u20131640","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR112","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"Ye X, Bo X, Hu X, Cui H, Lu B, Shao J et al (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-severe Graves\u2019 orbitopathy. Clin Endocrinol (Oxf) 86:247\u2013255","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"G Kahaly","year":"2018","unstructured":"Kahaly G, Riedl M, K\u00f6nig J, Pitz S, Ponto K, Diana T et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1258_CR114","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00002281-199905000-00012","volume":"11","author":"M Seitz","year":"1999","unstructured":"Seitz M (1999) Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 11:226\u2013232","journal-title":"Curr Opin Rheumatol"},{"key":"1258_CR115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14310\/horm.2002.1155","volume":"1","author":"L Bartalena","year":"2002","unstructured":"Bartalena L, Tanda M, Medea A, Marcocci C, Pinchera A (2002) Novel approaches to the management of graves\u2019 ophthalmopathy. Hormones (Athens) 1:76\u201390","journal-title":"Hormones (Athens)"},{"key":"1258_CR116","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/cen.13834","volume":"89","author":"Z Sipkova","year":"2018","unstructured":"Sipkova Z, Insull E, David J, Turner H, Keren S, Norris J (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol (Oxf) 89:834\u2013839","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1677\/jme.0.0250063","volume":"25","author":"D Pasquali","year":"2000","unstructured":"Pasquali D, Vassallo P, Esposito D, Bonavolont\u00e0 G, Bellastella A, Sinisi A (2000) Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves\u2019 ophthalmopathy. J Mol Endocrinol 25:63\u201371","journal-title":"J Mol Endocrinol"},{"key":"1258_CR118","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/jc.2006-1105","volume":"91","author":"M Stan","year":"2006","unstructured":"Stan M, Garrity J, Bradley E, Woog J, Bahn M, Brennan M et al (2006) Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 91:4817\u20134824","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR119","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF03344119","volume":"29","author":"L Tanda","year":"2006","unstructured":"Tanda L, Bartalena L (2006) Currently available somatostatin analogs are not good for Graves\u2019 orbitopathy. J Endocrinol Invest 29:389\u2013390","journal-title":"J Endocrinol Invest"},{"key":"1258_CR120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03344124","volume":"29","author":"T Chang","year":"2006","unstructured":"Chang T, Liao S (2006) Slow-release lanreotide in Graves\u2019 ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 29:413\u2013422","journal-title":"J Endocrinol Invest"},{"key":"1258_CR121","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM 230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and unique antisecretory profile. Eur J Endocrinol 146:707\u2013716","journal-title":"Eur J Endocrinol"},{"key":"1258_CR122","first-page":"735","volume":"64","author":"S Tahara","year":"2017","unstructured":"Tahara S, Murakami M, Kaneko T, Shimatsu A (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocrinol J 64:735\u2013747","journal-title":"Endocrinol J"},{"key":"1258_CR123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2265.1999.00681.x","volume":"50","author":"M Gerding","year":"1999","unstructured":"Gerding M, van der Zant F, van Royen E, Koornneef L, Krenning E, Wiersinga W et al (1999) Octreotide-scintigraphy is a disease-activity parameter in Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 50:373\u2013379","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1258_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2017.01.014","volume":"446","author":"F Tang","year":"2017","unstructured":"Tang F, Chen X, Mao Y, Wan S, Ai S, Yang H et al (2017) Orbital fibroblast of Graves\u2019 orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF. Mol Cell Endocrinol 446:1\u201311","journal-title":"Mol Cell Endocrinol"},{"key":"1258_CR125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.survophthal.2012.10.006","volume":"58","author":"S Shen","year":"2013","unstructured":"Shen S, Chan A, Sfikakis P, Hsiu Ling A, Detorakis E, Boboridis K et al (2013) B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol 58:252\u2013265","journal-title":"Surv Ophthalmol"},{"key":"1258_CR126","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2013-3207","volume":"99","author":"A McCoy","year":"2014","unstructured":"McCoy A, Kim D, Gillespie E, Atkins S, Smith T, Douglas R (2014) Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R (+) T cells. Clin Endocrinol Metab 99:1294\u20131299","journal-title":"Clin Endocrinol Metab"},{"key":"1258_CR127","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","volume":"67","author":"R van Vollenhoven","year":"2015","unstructured":"van Vollenhoven R, Wax S, Li Y, Tak P (2015) Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Reumatol 67:2828\u20132836","journal-title":"Arthritis Reumatol"},{"key":"1258_CR128","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S67264","volume":"9","author":"A Lenert","year":"2015","unstructured":"Lenert A, Lenert P (2015) Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF\/APRIL targeting agents. Drug Des Dev Ther 9:333\u2013347","journal-title":"Drug Des Dev Ther"},{"key":"1258_CR129","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders D, Grove R, Broderick C, Rudo T, Bassiri A et al (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:1425\u20131434","journal-title":"Neurology"},{"key":"1258_CR130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2011-2697","volume":"97","author":"L van Steensel","year":"2012","unstructured":"van Steensel L, Paridaens D, van Meurs M, van Hagen P, van den Bosch W, Kuijpers R et al (2012) Orbit-infiltrating mast cells, monocytes and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 97:400\u2013408","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR131","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","volume":"50","author":"L van Steensel","year":"2009","unstructured":"van Steensel L, Paridaens D, Schrijver B, Dingjan G, van Daele P, van Hagen P et al (2009) Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves\u2019 ophthalmopathy. Invest Ophthalmol Vis Sci 50:3091\u20133098","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1258_CR132","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"T Kim","year":"2013","unstructured":"Kim T, Rea D, Schwarz M, Grille P, Nicolini F, Rosti G et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316\u20131321","journal-title":"Leukemia"},{"key":"1258_CR133","doi-asserted-by":"crossref","first-page":"e95586","DOI":"10.1371\/journal.pone.0095586","volume":"9","author":"H Li","year":"2014","unstructured":"Li H, Fitchett C, Kozdon K, Jayaram H, Rose G, Bailly M et al (2014) Independent adipogenic and contractile properties of fibroblasts in Graves\u2019 orbitopathy: an in vitro model for the evaluation of treatments. PLoS ONE 9:e95586","journal-title":"PLoS ONE"},{"key":"1258_CR134","doi-asserted-by":"crossref","first-page":"e28555","DOI":"10.1371\/journal.pone.0028555","volume":"6","author":"A Borriello","year":"2011","unstructured":"Borriello A, Caldarelli I, Basile M, Bencivenga D, Tramontano A, Perrotta S et al (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS ONE 6:e28555","journal-title":"PLoS ONE"},{"key":"1258_CR135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00417-014-2674-7","volume":"252","author":"S Virakul","year":"2014","unstructured":"Virakul S, Dalm V, Paridaens D, van den Bosch W, Hirankarn N, van Hagen P et al (2014) The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation. Graefes Arch Clin Exp Ophthalmol 252:1101\u20131109","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1258_CR136","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/jc.2013-4182","volume":"99","author":"L Zhang","year":"2014","unstructured":"Zhang L, Grennan-Jones F, Draman M, Lane C, Morris D, Dayan C et al (2014) Possible targets for nonimmunosuppressive therapy of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 99:1183\u20131190","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR137","first-page":"2463","volume":"32","author":"J Kurtz","year":"2012","unstructured":"Kurtz J, Ray-Coquard I (2012) PI3 kinase inhibitors in the clinic: an update. Anticancer Res 32:2463\u20132470","journal-title":"Anticancer Res"},{"key":"1258_CR138","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jc.2012-3080","volume":"97","author":"M Gershengorn","year":"2012","unstructured":"Gershengorn M, Neumann S (2012) Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 97:4287\u20134292","journal-title":"J Clin Endocrinol Metab"},{"key":"1258_CR139","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","volume":"48","author":"R Fleischmann","year":"2003","unstructured":"Fleischmann R, Schechtman J, Bennett R, Handel M, Burmester G, Tesser J et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48:927\u2013934","journal-title":"Arthritis Rheum"},{"key":"1258_CR140","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","volume":"149","author":"A Daifotis","year":"2013","unstructured":"Daifotis A, Koenig S, Chatenoud L, Herold K (2013) Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 149:268\u2013278","journal-title":"Clin Immunol"},{"key":"1258_CR141","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1167\/iovs.14-14008","volume":"55","author":"S Rhiu","year":"2014","unstructured":"Rhiu S, Chae M, Lee E, Lee J, Yoon J (2014) Effect of tanshinone IIA in an in vitro model of Graves\u2019 orbitopathy. Invest Ophthalmol Vis Sci 55:5900\u20135910","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1258_CR142","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-09-0383","volume":"16","author":"S Estcourt","year":"2009","unstructured":"Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B (2009) The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol 16:483\u2013487","journal-title":"Eur J Endocrinol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-019-01258-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01258-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:05:16Z","timestamp":1610064316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-019-01258-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s10792-019-01258-7","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"27 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}